HemoSonics

Executive Summary

HemoSonics is a US-based diagnostics company commercializing the Quantra® System, a point-of-care and laboratory viscoelastic testing platform that delivers rapid, precise hemostasis analysis. In critical care settings such as cardiac surgery, trauma, and obstetrics, the Quantra® System enables clinicians to make data-driven blood management decisions, potentially reducing unnecessary blood product transfusions, complications, and hospital costs. By offering faster results and easier operation compared to conventional methods (e.g., TEG/ROTEM), HemoSonics aims to improve patient outcomes and drive efficiency in high-acuity environments. The company's technology addresses a significant clinical need for real-time coagulation monitoring, positioning it for adoption in operating rooms, emergency departments, and intensive care units. As a private company with a commercially available product, HemoSonics' near-term growth hinges on securing regulatory clearances for expanded indications, generating robust clinical evidence, and forging strategic partnerships to scale commercialization. The global hemostasis diagnostics market is expanding, driven by increased awareness of coagulopathy in trauma and surgery. Key upcoming milestones include potential FDA clearance for trauma/obstetric applications, publication of pivotal clinical data, and distribution agreements with established medical device companies. While competition from legacy viscoelastic testing platforms exists, the Quantra® System's unique design and workflow advantages could drive adoption and market share gains.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded indications (trauma, obstetrics)70% success
• Q2 2026Publication of pivotal clinical data in peer-reviewed journals80% success
• Q4 2026Strategic distribution or partnership agreement with a leading diagnostics player50% success